



CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By: Lewis J. Kreisler
Lewis J. Kreisler
Reg. No. 38522

Date: 7-11-05

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	John C. Bell, et al.	Atty. Ref	18003-D2
Appl. No.:	10/743,649	Group Art Unit:	1645
Filed:	December 22, 2003	Examiner:	Robert A. Zeman
Title:	ONCOLYTIC VIRUS		

* * * * *

July 11, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. A copy of each listed document is enclosed.

The July 11, 2005 Office Action acknowledged citation of the enclosed references but noted that not all of the references were available to the Examiner. Applicants are filing this Supplemental IDS to provide replacement copies of the documents as a courtesy to the Examiner.

Inventor(s): Bell, et al.
Application No.: 10/743,649
Page 2

Because the documents submitted herewith were already submitted in the parent application, it is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,

A handwritten signature in cursive script, reading "Lewis J. Kreisler".

Lewis J. Kreisler

Reg. No. 38522

Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTG 45

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1
-------	---

of	3
----	---

Complete if Known

Application Number	10/743,649
Filing Date	December 22, 2003
First Named Inventor	John C. Bell
Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003-D2

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/743,649
		Filing Date	December 22, 2003
		First Named Inventor	John C. Bell
		Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 2	of 3	Attorney Docket Number	18003-D2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KIRN, et al., "ONYX-015 selectively replicates in and lyses cells lacking functional p53", Proceedings for the American Associates for Cancer Research, Vol. 37, pages 352, March 1996. Abstract 2400.	
		KALVAKOLANU, et al., "Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF-kB in mouse embryonal carcinoma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, pages 3167-3171, April 1993.	
		LORENCE, et al., "Complete Regression of Human Fibrosarcoma Xenografts Mice after Local Newcastle Disease Virus Therapy", Cancer Research, Vol. 54, pages 6017-6021-December 1, 1994.	
		LORENCE, et al., "Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice after Local Newcastle Disease Virus Therapy", Journal of the National Cancer Institute, Vol. 86, No. 16, pages 1228-1233, August 17, 1994.	
		AHLERT, et al., "Isolation of Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Replication Patterns", Cancer Res. Vol. 50, pages 5962-5968, 1990.	
		ABRAHAM, et al., "The Murine PKR Tumor Suppressor Gene is Rearranged in a Lymphocytic Leukemia", Experimental Cell Research, Vol. 244, pages 394-404, 1998, Article No. EX984201.	
		ABRAHAM, et al., "Characterization of Transgenic Mice with Targeted Disruption of the Catalytic Domain of the Double-stranded RNA-dependent Protein Kinase, PKR", The Journal of Biological Chemistry, Vol. 274, No. 9, pages 5953-5962, 1999.	
		BERETTA, et al., "Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q-associated leukemias", Oncogene, Vol. 12, pages 1593-1596, 1996.	
		DONZE, et al., "Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells", The EMBO Journal, Vol. 14, No. 15, pages 3828-3834, 1995.	
		GALE, Jr., et al., "Evidence that Hepatitis C Virus Resistance to Interferon is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein", Virology, Vol. 230, pages 217-227, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/743,649
		Filing Date	December 22, 2003
		First Named Inventor	John C. Bell
		Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 3	of 3	Attorney Docket Number	18003-D2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KUMAR, et al., "Double-Stranded RNA-Activated Protein Kinase (PKR) is Negatively Regulated by 60S Ribosomal Subunit Protein L18", Molecular and Cellular Biology, pages 1116-1125, February 1999.	
		MELVILLE, et al., "The Molecular Chaperone hsp40 Regulates the Activity of P58IPK, the cellular inhibitor of PKR", Proc. Natl. Acad. Sci. USA, Vol. 94, pages 97-102, January 1997.	
		MUNDSCHAU, et al., "Endogenous Inhibitors of the dsRNA-dependent eIF-2 α protein kinase PKR in normal and ras-transformed cells", Biochimie, Vol. 76, pages 792-800, 1994.	
		SAVINOVA, et al., "Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells", The International Journal of Biochemistry & Cell Biology, Vol. 31, pages 175-189, 1999.	
		STRONG, et al., "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", The EMBO Journal, Vol. 17, No. 12, pages 3351-3362, 1998.	
		STOJDL, et al., "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus", Nature Medicine, Vol. 6, No. 7, pages 821-825, July 2000.	
		STOJDL, et al., "The Murine Double-Stranded RNA-Dependent Protein Kinase PKR is Required for Resistance to Vesicular Stomatitis Virus", Journal of Virology, Vol. 74, No. 20, pages 9580-9585, October 2000.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.